

May 13, 2010

To those concerned

R-Tech Ueno, Ltd.
(Code No.4573, Osaka Securities Exchange; Hercules)
Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo
Representative: Yukihiro Mashima,
Representative Director & President
Contact: Koji Nakamura, Business Management Department;
TEL: 03-(3596) 8011

Announcement of License Agreement for Rescula[®] Eye Drops with Novartis Pharma

R-Tech Ueno, Ltd. has started the negotiation with Novartis Pharma AG to terminate the License Agreement for Rescula[®] Eye Drops under which R-Tech Ueno had granted Novartis Pharma AG the rights for the development and commercialization of Rescula[®] Eye Drops (generic name; isopropyl unoprostone) in overseas markets (except Taiwan, Korea and North America). R-Tech Ueno has made this decision under the result of examining the growth strategy of Rescula[®] Eye Drops carefully in consideration of the existing condition of the royalty income which R-Tech Ueno received. Once the termination of the agreement is completed, R-Tech Ueno will seek opportunities for developing and selling the product by itself or through new marketing partners in the territory which Novartis Pharma AG had been granted.

• About R-Tech Ueno, Ltd.

R-Tech Ueno is a bio venture company established in September 1989 for the purpose of marketing and R&D of drugs. Under leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme “Physician-Oriented New Drug Innovation”, targeting ophthalmologic and dermatologic diseases that previously had no effective therapeutic agent.

We aim at becoming a “global pharmaceutical company specializing in specific fields (ophthalmology and dermatology) and selling and developing pharmaceutical products through the eyes of doctors.” We are promoting development of new drugs of unmet medical needs (medical needs that are not fulfilled yet) which the government recommends and assists, orphan drugs and the drugs in the field of anti-aging (lifestyle drugs).